Loading ...

A Research Trial Of Aralast In New Onset Diabetes

(

RETAIN

)

ITN Protocol #:

ITN041AI

Branded Name:

RETAIN

ClinicalTrials.Gov ID:

NCT01183468

Treatment Protocol #:

AAT

Therapeutic Area:

Type 1 Diabetes

Current Status:

Completed

Summary:

Effect of Intravenous Alpha-1 Antitrypsin on Preserving Beta-cell Function in New-onset Type 1 Diabetes Mellitus

Clinical Operations Associate Director

ITN Clinical Trials Physician

NIAID Project Manager

Study Personnel:

Protocol Chair

Gordon Weir, MDgordon.weir@joslin.harvard.edu

Work: 

617-496-4050

Protocol Chair

Carol Soppecsoppe@immunetolerance.org

Work: 

415-353-4879

Protocol Chair

Srinath Sanda, MDssanda@immunetolerance.org

Work: 

415-353-4414

Protocol Chair

Peggy Fitzgibbonpeggy.fitzgibbon@nih.gov

Work: 

240-627-3505